The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.

Yelena Y.  Janjigian

Stock and Other Ownership Interests  - Inspirna

Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Master Clinician Alliance; Merck; Michael J. Hennessy Associates; Peerview; Research to Practice

Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Guardant Health; Imedex; Imugene; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks

Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst); Transcenta (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck

Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice

Salah-Eddin  Al-Batran

Stock and Other Ownership Interests  - Immutep; Institut für Klinische Krebsforschung GmbH

Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme

Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group

Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma

Zev A.  Wainberg

Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen

Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)

Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck

Eric  Van Cutsem

Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks

Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)

Daniela  Molena

Honoraria - Bristol-Myers Squibb/Pfizer; Merck

Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Boston Scientific; Johnson & Johnson; medtronic

Kei  Muro

Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda

Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Solasia Pharma

Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)

Woo Jin  Hyung

Employment - Hutom

Stock and Other Ownership Interests  - Hutom

Consulting or Advisory Role - SK Hynix

Research Funding - GC Pharma; Medtronic

Lucjan S.  Wyrwicz

Honoraria - BeiGene; BMS; MSD

Consulting or Advisory Role - GlaxoSmithKline; SERVIER

Speakers' Bureau - BMS

Travel, Accommodations, Expenses - SERVIER

Do-Youn  Oh

Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks

Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER

Takeshi  Omori

Honoraria - DAIICHI SANKYO COMPANY, LIMITED

Research Funding - DAIICHI SANKYO COMPANY, LIMITED (Inst)

Markus  Moehler

Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier; Transcenta; Triptych Health Partners

Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; Nordic Group; SERVIER; Taiho Pharmaceutical

Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur

Marcelo  Garrido

Consulting or Advisory Role - AstraZeneca; MSD; Roche

Speakers' Bureau - Bayer; Bristol-Myers Squibb; MERCK

Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)

Expert Testimony - AstraZeneca

Travel, Accommodations, Expenses - Roche

Sulene CS  Oliveira

No Relationships to Disclose

Moishe  Liberman

Stock and Other Ownership Interests  - AssistIQ; Ditch Labs; Endocision

Consulting or Advisory Role - Johnson and Johnson

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Sanofi (Inst); Cook Medical (Inst); Ethicon/Johnson & Johnson (Inst); Johnson & Johnson/MedTech (Inst); Merck (Inst); Pfizer (Inst)

Patents, Royalties, Other Intellectual Property - Cryobiopsy Device

Victor  Castro Oliden

No Relationships to Disclose

Mehmet  Bilici

No Relationships to Disclose

John F.  Kurland

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca; Bristol-Myers Squibb/Celgene

Patents, Royalties, Other Intellectual Property - 1) ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER 2) METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES (Inst)

Travel, Accommodations, Expenses - AstraZeneca

Ioannis  Xynos

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Helen  Mann

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Josep  Tabernero

Stock and Other Ownership Interests  - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo

Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource